PD 136450
PD 136450 Basic information
- Product Name:
- PD 136450
- Synonyms:
-
- PD 136450
- (E)-4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobut-2-enoic acid
- Cam 1189
- Cam1189
- Cam-1189
- 2-Butenoic acid, 4-[[(1R)-2-[[(2R)-3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo[3.3.1.13,7]dec-2-yloxy)carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxo-
- CAS:
- 139067-52-0
- MF:
- C35H40N4O6
- MW:
- 612.72
- Mol File:
- 139067-52-0.mol
PD 136450 Chemical Properties
- Boiling point:
- 950.4±65.0 °C(Predicted)
- Density
- 1.33±0.1 g/cm3(Predicted)
- pka
- 3.49±0.10(Predicted)
PD 136450 Usage And Synthesis
Description
Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role of gastrin, have therapeutic potential as acid antisecretory drugs, and may be of use as adjuvant therapy for gastrin sensitive tumours. The agonist effect of PD-136,450 is mediated via interaction with the gastrin (CCK-B) receptor in the stomach and the CCK-A receptor in the pancreas.
Uses
PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats[1].
References
[1] Bastaki SM, et al., PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity. Mol Cell Biochem. 2003 Oct;252(1-2):83-90. DOI:10.1023/a:1025566919581